



衛生福利部
MINISTRY OF HEALTH AND WELFARE

CERTIFICATE OF GOOD MANUFACTURING PRACTICE

Issue Date: October 12, 2022

Issued following an inspection in accordance with Article 57 of the Pharmaceutical Affairs Law and relevant Regulations of the Republic of China (Taiwan).

The competent authority of the Republic of China confirms the following:

The manufacturer: Chirogate International Inc. Wulin Plant

Site address: No.41, Sec. 1, Gong 2nd Rd., and No. 22, Alley 39, Sec. 1, Gong 2nd Rd., Longtan Dist., Taoyuan City 325019, Taiwan

Manufacturer's licence number: (C)0022005

is the manufacturer of medicinal products for human use that has been inspected with the following Active Pharmaceutical Ingredient(s): Latanoprost.

From the knowledge gained during GMP inspection performed on August 11-12, 2022, it is considered that the manufacturer complies with the Pharmaceutical Inspection Convention/Cooperation Scheme Guide to Good Manufacturing Practice for medicinal products (PIC/S GMP) Part II (=GMP of WHO/ICH Q7).

This certificate is valid until April 24, 2026.

This certificate may be revoked at anytime as warranted.

Signed by

Shou-Mei Wu

Shou-Mei Wu, Ph.D.

Director-General

Food and Drug Administration

(<http://www.fda.gov.tw/TC/index.aspx>)

Under the delegated authority of

Shih-Chung Chen, D.D.S.

Minister

Ministry of Health and Welfare

Republic of China (Taiwan)

